Latest filing published 07 Nov 2025 for Madrigal Pharmaceuticals, INC., €45k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Kenneth Bate across 3 companies, led by Madrigal Pharmaceuticals, Inc., Epizyme, Inc. and Aveo Pharmaceuticals, Inc. We count 12 filings; the first trade dates from 11 June 2021 and the latest from 5 November 2025.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The record was last updated on 7 November 2025 with an option exercise (€45k) in Madrigal Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations